Press Releases

Filters (3)
February 26, 2019

Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections

Read more
January 10, 2017

Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients

Read more
October 25, 2016

Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450

Read more
April 8, 2016

Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID

Read more
April 23, 2015

Debiopharm International SA initiates clinical phase II study evaluating Debio 1450 in Staphylococcal skin infections

Read more
January 8, 2015

FDA Grants Fast Track designation to Debiopharm Group’s antibiotic Debio 1450

Read more
October 7, 2014

Debiopharm Group™ Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450, its Potent Anti-staphylococcal Agent

Read more
September 4, 2014

Debiopharm Group™’s innovative antibiotic Debio 1450 – developed from its proprietary plateform Fabiotics – Receives Qualified Infectious Disease Product (QIDP)…

Read more
June 19, 2014

Debiopharm Group™ Announces Initiation of a Phase I Study of Debio 1450, an IV/oral Potent Antibiotic Active Against Staphylococcal Infections

Read more